Your session is about to expire
← Back to Search
Neoadjuvant Enoblituzumab for Prostate Cancer (HEAT Trial)
HEAT Trial Summary
This trial evaluates a therapy (enoblituzumab) given before surgery to treat prostate cancer. Patients will be randomly assigned to receive the therapy or standard care.
HEAT Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowHEAT Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 1 trial • 3 Patients • NCT04630769HEAT Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Has Enoblituzumab been granted clearance by the Federal Drug Administration?
"Taking into account the Phase 2 status of Enoblituzumab, Power assessed its safety as a 2 on their scale. This is due to limited evidence for efficacy while some data points exist which attest to safety."
Are there any remaining vacancies for this research study?
"According to the current information on clinicaltrials.gov, this particular medical study is no longer enrolling individuals as it was last updated in August of 2023. Nevertheless, there are still 1356 alternative trials actively seeking participants for their respective research projects."
Share this study with friends
Copy Link
Messenger